Literature DB >> 33572452

Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.

Steve Pascolo1.   

Abstract

In the race for a vaccine against SARS-CoV-2, the synthetic mRNA format has been shown to be the fastest one and proved to be safe and highly efficient, even at the very low dose of a few µg per injection. The mRNA vaccines are not new: vaccines that are based on attenuated mRNA viruses, such as Mumps, Measles, and Rubella, immunize by delivering their mRNAs into the cells of the vaccinated individual, who produces the viral proteins that then prime the immune response. Synthetic mRNA in liposomes can be seen as a modern, more refined, and thereby a safer version of those live attenuated RNA viruses. The anti-COVID-19 mRNA vaccine (coding the SARS-CoV-2 spike protein) is the third synthetic RNA therapeutic being approved. It follows the aptamer Macugen® (which neutralizes VEGF) and the siRNA Onpattro® (which destroys the transthyretin-coding mRNA). Remarkably, the 30 µg of mRNA that are contained in the first approved anti-COVID-19 vaccine are sufficient for generating high levels of neutralizing antibodies against the virus in all injected volunteers (including participants over 65 years old). The efficacy and safety data are stunning. The distribution of these vaccines throughout the world will bring a halt to the coronavirus pandemic.

Entities:  

Keywords:  SARS-CoV-2; mRNA; spike protein; vaccine

Year:  2021        PMID: 33572452     DOI: 10.3390/v13020270

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  18 in total

1.  Antibody-Based Affinity Capture Combined with LC-MS Analysis for Identification of COVID-19 Disease Serum Biomarkers.

Authors:  Paul C Guest; Hassan Rahmoune
Journal:  Methods Mol Biol       Date:  2022

2.  Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine: A Case Report.

Authors:  Bruno Bouça; Marisa Roldão; Paula Bogalho; Luís Cerqueira; José Silva-Nunes
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

3.  Where are the RNA vaccines for TB?

Authors:  Xiao-Yong Fan; Douglas Bruce Lowrie
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

Review 4.  Review the safety of Covid-19 mRNA vaccines: a review.

Authors:  Pratibha Anand; Vincent P Stahel
Journal:  Patient Saf Surg       Date:  2021-05-01

Review 5.  Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective.

Authors:  Dennis Niebel; Natalija Novak; Jasmin Wilhelmi; Jana Ziob; Dagmar Wilsmann-Theis; Thomas Bieber; Joerg Wenzel; Christine Braegelmann
Journal:  Vaccines (Basel)       Date:  2021-08-25

Review 6.  From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies.

Authors:  Hironori Adachi; Martin Hengesbach; Yi-Tao Yu; Pedro Morais
Journal:  Biomedicines       Date:  2021-05-14

Review 7.  Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.

Authors:  Uttpal Anand; Shweta Jakhmola; Omkar Indari; Hem Chandra Jha; Zhe-Sheng Chen; Vijay Tripathi; José M Pérez de la Lastra
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

Review 8.  Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients.

Authors:  Emanuela Romano; Steve Pascolo; Patrick Ott
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

Review 9.  Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.

Authors:  Javier T Granados-Riveron; Guillermo Aquino-Jarquin
Journal:  Biomed Pharmacother       Date:  2021-07-23       Impact factor: 6.529

Review 10.  mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles.

Authors:  Andreas Ouranidis; Theofanis Vavilis; Evdokia Mandala; Christina Davidopoulou; Eleni Stamoula; Catherine K Markopoulou; Anna Karagianni; Kyriakos Kachrimanis
Journal:  Biomedicines       Date:  2021-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.